Every year on February 4, the world pauses to observe World Cancer Day. Led by the Union for International Cancer Control (UICC), it’s a global call to come together through awareness, education, and action.
The 2025–2027 theme, “United by Unique,” captures how no two cancer journeys look the same. Yet, patients, caregivers, clinicians, and innovators are united by a shared goal to fight for personalised, accessible care for all (UICC, 2026).
In 2026, World Cancer Day means something more. The conversation has moved beyond lifestyle advice and early screening alone. Today, it’s also about the tech revolution that is transforming cancer care for good.
Cancer is now a global health challenge
Cancer remains one of the biggest threats to global health, and the numbers are hard to ignore. In 2025 alone, the U.S. reported more than 2 million new cancer cases and nearly 618,000 deaths. Worldwide, the pressure is rising, fueled by aging societies, environmental risks and lifestyle changes.
Today, roughly 1 in 5 people will face cancer in their lifetime. And survival rates have also improved significantly; nearly 70% of patients now survive five years or more.
But healthcare systems are under immense pressure. The volume of patients is simply overwhelming.
And healthtech is helping address that. It is becoming the backbone of modern cancer care.
Spotlight: 5 healthtech startups redefining cancer care
In 2025, oncology became the highest-funded vertical in healthcare technology. According to HealthTech Alpha, $7.2 Bn (the highest) of $44 Bn raised last year went to cancer care startups.
The sector is attracting venture capital as investors bet on AI and precision medicine to solve the “unsolvable” disease.
Here are a few startups leading the charge:
Tempus AI
Founder: Eric Lefkofsky
Year: 2015 | Location: Chicago
A leader in precision medicine, Tempus uses AI to analyze one of the world’s largest libraries of clinical and molecular data, helping oncologists tailor treatments to a patient’s specific genetic profile.
GRAIL
Founder: Bob Ragusa (Chief Executive Officer)
Year: 2015 | Location: California
Famous for its “Galleri” test, GRAIL is a pioneer in multi-cancer early detection (MCED). Their liquid biopsy technology can detect over 50 types of cancer from a single blood draw, often before symptoms appear.
Triomics
Founder: Sarim Khan (Co-founder and CEO), Hrituraj Singh (Co-founder and CTO)
Year: 2021 | Location: U.S.A
This startup addresses a massive logistical bottleneck by using its “OncoLLM” (a specialised Large Language Model) to extract unstructured data from medical records. This allows for 100% screening of patients for clinical trial eligibility, ensuring no one misses out on life-saving experimental therapies.
Niramai Health Analytix
Founder: Geetha Manjunath (Founder, CEO and CTO)
Year: 2016 | Location: India
Niramai offers a non-invasive, radiation-free breast cancer screening solution using “Thermalytix”. It’s an AI-based thermal imaging tool that is affordable and accessible for rural populations.
Flatiron Health
Founder: Nat Turner (CEO) and Zach Weinberg (COO)
Year: 2012 | Location: New York
To accelerate drug development and enhance treatment quality, Flatiron creates a unified data platform. This platform harnesses real-world evidence by bridging the gap between community oncologists and cancer researchers.
How healthtech innovators can further address the tech gap in cancer care
The paradox of modern oncology is that we don’t lack data; we’re drowning in it. Nearly 80% of patient information is unstructured, locked away in handwritten notes, scanned documents, and disconnected systems. We have big data, but it doesn’t talk to itself.
Here’s how healthtech innovators can bridge this divide:
1. Build to connect
Healthtech solutions must be interoperable by design. True progress will come from “plug-and-play” systems that allow seamless data flow. Be it at a local clinic in a developing nation or a leading global research centre across borders.
2. Go beyond detection
With AI entering its Agentic phase, solutions must move beyond just spotting tumours earlier. They must now be able to predict recurrence years in advance by analyzing subtle signals like changes in voice, movement patterns, or metabolism.
3. Democratise precision care
Genomic sequencing and personalised therapies are still expensive. The next breakthrough must be making these “unique” insights affordable. Precision care must be affordable and accessible, not limited to a privileged few.
The path forward
World Cancer Day 2026 reminds us that the future of oncology isn’t just about better technology; it’s about better outcomes.
As HealthTech makes care more personalised, predictive, and accessible, innovation must translate into impact for every patient, everywhere.
It’s time cancer patients receive personalised care based on their unique symptoms.
-By Alkama Sohail and the AHT Team
